GENEREX BIOTECHNOLOGY CORPORATION (OTCMKTS:GNBT) Files An 8-K Financial Statements and Exhibits
Item 9.01(a) and the Pro Forma Financial Information required by Item 9.01(b). The financial statements and pro forma financial information is being filed by this Amendment.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired in accordance with Item 9.01(a) is included in this Amendment following the page.
| (i) | Audited Consolidated Financial Statements of Veneto Holdings, LLC as of and for the years ended December 31, 2016 and 2017 are attached as Exhibit 99.2 to this Current Report on Form 8-K/A. |
| (ii) | Unaudited Consolidated Balance Sheet as of June 30, 2018 and December 31, 2017 and the related unaudited Consolidated Statements of Operations, Changes in Equity and Consolidated Statements of Cash Flows for the six month periods ended June 30, 2018 and 2017 of Veneto Holdings, LLC are attached as Exhibit 99.3 to this Current Report on Form 8-K/A. |
(b) Pro forma financial information
Pro forma financial information required by Item 9.01(c) of Form 8-K related to the Acquisition is attached as Exhibit 99.4 to this Current Report on Form 8-K/A.is included in this Amendment following the page.
| (i) | Unaudited Pro Forma Condensed Combined Balance Sheet as of July 31, 2018. |
| (ii) | Unaudited Pro Forma Condensed Combined Statement of Operations for the year ended July 31, 2018. |
(d)Exhibits.
| Exhibit Number | Description of Exhibit |
| 10.1 | Asset Purchase Agreement by and between Veneto Holdings, L.L.C. and NuGenerex Distribution Solutions, LLC effective October 3, 2018.* |
| 10.2 | Amendment to Asset Purchase Agreement by and between Veneto Holdings, L.L.C. and NuGenerex Distribution Solutions 2, LLC effective November 1, 2018.* |
| 10.3 | Promissory Note in the amount of $15,000,000 from NuGenerex Distribution Solutions, LLC to Veneto Holdings, LLC.* |
| 10.4 | Promissory Note in the amount of $35,000,000 from NuGenerex Distribution Solutions 2, LLC to Veneto Holdings, LLC.* |
| 99.1 | Audited consolidated financial statements of Generex Biotechnology Corporation for the fiscal years ended July 31, 2018 and 2017 including the report of MNP, LLC on such audited financial statements, filed with the Securities and Exchange Commission on October 26, 2018.* |
| 99.2 | Audited consolidated financial statements of Veneto Holdings, LLC for the years ended December 31, 2017 and 2016 including the report of Whitley Penn LLP on the 2017 audited financial statements. |
| 99.3 | Unaudited pro forma condensed combined financial information as of and for the twelve-month period ended July 31, 2018. |
| 99.4 | Press release dated October 9, 2018 issued by Generex Biotechnology Corporation* |
| 99.5 | Press release dated November 2, 2018 issued by Generex Biotechnology Corporation* |
| 99.6 | Unaudited consolidated financial statements for Veneto Holdings, LLC as of June 30, 2018 and December 31, 2017 and for the six months ended June 30, 2018 and 2017 |
*Previously filed with the Original Reports.
GENEREX BIOTECHNOLOGY CORP Exhibit
EX-99.3 2 ex99_3.htm EXHIBIT 99.3 Exhibit 99.3 Unaudited pro forma condensed combined financial information The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the acquisition of substantially all the assets primarily used in ancillary health care service providers,…
To view the full exhibit click here
About GENEREX BIOTECHNOLOGY CORPORATION (OTCMKTS:GNBT)
Generex Biotechnology Corporation is a development-stage company. The Company is engaged primarily in the research and development of drug delivery systems and technologies. The Company is focused on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its buccal delivery technology is a platform technology that has application to various large molecule drugs and provides a non-invasive way to administer such drugs. The Company focuses its development efforts on Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its hand-held aerosol spray applicator known as RapidMist. Its subsidiary, Antigen Express, Inc., focuses on developing vaccine formulations that work by stimulating the immune system to either attack offending agents, such as cancer cells, bacteria and viruses, or to stop attacking benign elements, such as self proteins and allergens.
